Thrombocytopenia associated with the use of anti–tumor necrosis factor–⍺ agents for psoriasis - 07/08/11
Abstract |
Background |
Thrombocytopenia has been reported to be associated with efalizumab therapy, but has only sporadically been reported with other anti–tumor necrosis factor alfa (TNF-⍺) agents.
Objective |
To describe the frequency of thrombocytopenia in a cohort of patients who underwent biological therapies for psoriasis.
Methods |
This was a retrospective observational study of 93 patients.
Results |
One hundred eighteen courses of biological therapies were administered to 93 patients. Four of 67 patients who received anti-TNF-⍺ agents developed drug-induced thrombocytopenia during treatment, compared with none of the 51 patients receiving efalizumab therapy. The platelet count recovered after suspension of anti-TNF-⍺ agents in 3 patients and relapsed after re-exposure in two patients. The overall estimated frequency of thrombocytopenia in our cohort was 4.30% (95% confidence interval [CI], 0% to 6.2%).
Limitations |
These findings should be validated in larger studies.
Conclusions |
Drug-induced thrombocytopenia is a potential side effect of anti-TNF-⍺ agents. Immediate monitoring of platelet counts is recommended if autoimmunity is suspected.
Le texte complet de cet article est disponible en PDF.Key words : adalimumab, efalizumab, etanercept, infliximab, psoriasis, thrombocytopenia
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 60 - N° 5
P. 781-785 - mai 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?